Literature DB >> 18027021

Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection.

Kazuyuki Nagai1, Ryuichiro Doi, Atsushi Kida, Kazuhiro Kami, Yoshiya Kawaguchi, Tatsuo Ito, Takaki Sakurai, Shinji Uemoto.   

Abstract

BACKGROUND: Resection is recommended for main duct intraductal papillary mucinous neoplasms (IPMNs) of the pancreas because of the high risk of malignancy, but the indications for resection of branch duct and mixed-type IPMNs remain controversial. Our objective was to determine the appropriate management of IPMNs based on clinicopathologic characteristics and survival data obtained after resection.
METHODS: A total of 72 consecutive IPMN patients who underwent resection between January 1984 and June 2006 were reviewed. The lesions were classified as main duct, branch duct, or mixed-type IPMNs and histologically graded as noninvasive (adenoma, borderline neoplasm, carcinoma in situ) or invasive.
RESULTS: Main duct IPMNs (n=15) were associated with a significantly worse prognosis than other subtypes. For branch duct (n=49) and mixed-type IPMNs (n=8), the diameter of the cystic lesions was an independent predictor of malignancy by multivariate analysis. However, four patients with cysts<30 mm in diameter and no mural nodules had a malignancy. No patient with noninvasive IPMN died of this disease, showing excellent survival, whereas the 5-year survival rate of patients with invasive IPMNs was only 57.6% and was significantly worse than that of patients with noninvasive IPMNs (p=0.0002).
CONCLUSIONS: Resection of all main duct IPMNs seems to be reasonable. Invasive IPMNs were associated with significantly worse survival than noninvasive IPMNs. Although the diameter of cystic lesions was a predictor of malignancy for branch duct and mixed-type IPMNs, precise preoperative identification of malignancy was difficult. Therefore, these lesions should be managed by aggressive resection before invasion occurs to improve survival.

Entities:  

Mesh:

Year:  2008        PMID: 18027021     DOI: 10.1007/s00268-007-9281-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

1.  Diagnosis and management of cystic pancreatic tumours with mucin production.

Authors:  Y Shima; M Mori; N Takakura; T Kimura; T Yagi; N Tanaka
Journal:  Br J Surg       Date:  2000-08       Impact factor: 6.939

Review 2.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

3.  Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Keita Wada; Richard A Kozarek; L William Traverso
Journal:  Am J Surg       Date:  2005-05       Impact factor: 2.565

4.  Evaluation of various imaging methods in the differential diagnosis of intraductal papillary-mucinous tumor (IPMT) of the pancreas.

Authors:  K Yamao; K Ohashi; T Nakamura; T Suzuki; Y Watanabe; Y Shimizu; Y Nakamura; I Ozden
Journal:  Hepatogastroenterology       Date:  2001 Jul-Aug

5.  Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas.

Authors:  M Sugiyama; Y Izumisato; N Abe; T Masaki; T Mori; Y Atomi
Journal:  Br J Surg       Date:  2003-10       Impact factor: 6.939

6.  Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor.

Authors:  Yutaka Suzuki; Yutaka Atomi; Masanori Sugiyama; Shuji Isaji; Kazuo Inui; Wataru Kimura; Makoto Sunamura; Toru Furukawa; Akio Yanagisawa; Jo Ariyama; Tadahiro Takada; Hidenobu Watanabe; Koichi Suda
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

7.  Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.

Authors:  T Inokuma; N Tamaki; T Torizuka; Y Magata; M Fujii; Y Yonekura; T Kajiyama; G Ohshio; M Imamura; J Konishi
Journal:  Radiology       Date:  1995-05       Impact factor: 11.105

8.  Surgical management of intraductal papillary mucinous tumor of the pancreas.

Authors:  Ryuichiro Doi; Koji Fujimoto; Michihiko Wada; Masayuki Imamura
Journal:  Surgery       Date:  2002-07       Impact factor: 3.982

9.  Mucin-hypersecreting tumors of the pancreas: assessing the grade of malignancy preoperatively.

Authors:  K Yamaguchi; Y Ogawa; K Chijiiwa; M Tanaka
Journal:  Am J Surg       Date:  1996-04       Impact factor: 2.565

10.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more
  42 in total

Review 1.  Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis.

Authors:  Robert Grützmann; Stefan Post; Hans Detlev Saeger; Marco Niedergethmann
Journal:  Dtsch Arztebl Int       Date:  2011-11-18       Impact factor: 5.594

2.  Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms.

Authors:  Jin Hee Lee; Kyu Taek Lee; Jongwook Park; Sun Youn Bae; Kwang Hyuck Lee; Jong Kyun Lee; Kee-Taek Jang; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi; Jong Chul Rhee
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 3.  IPMN: surgical treatment.

Authors:  Reto M Käppeli; Sascha A Müller; Bianka Hummel; Christina Kruse; Philip Müller; Jürgen Fornaro; Alexander Wilhelm; Marcel Zadnikar; Bruno M Schmied; Ignazio Tarantino
Journal:  Langenbecks Arch Surg       Date:  2013-09-03       Impact factor: 3.445

Review 4.  [Intraductal papillary mucinous neoplasia: which findings support observation?].

Authors:  J Mayerle; M Kraft; P Menges; P Simon; J Ringel; L I Partecke; C D Heidecke; M M Lerch
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

5.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

Review 6.  Pearls and pitfalls of imaging features of pancreatic cystic lesions: a case-based approach with imaging-pathologic correlation.

Authors:  Kumi Ozaki; Hiroshi Ikeno; Yasuharu Kaizaki; Kazuya Maeda; Shohei Higuchi; Nobuyuki Kosaka; Hirohiko Kimura; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2020-08-25       Impact factor: 2.374

7.  Pancreatic and extrapancreatic lesions in patients with intraductal papillary mucinous neoplasms of the pancreas: a single-centre experience.

Authors:  L Calculli; R Pezzilli; C Brindisi; R Morabito; R Casadei; M Zompatori
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

8.  Intraductal papillary mucinous neoplasms of the pancreas: radiological predictors of malignant transformation and the introduction of bile duct dilation to current guidelines.

Authors:  Albert Strauss; Matthew Birdsey; Stefan Fritz; Bogata D Schwarz-Bundy; Frank Bergmann; Thilo Hackert; Hans-Ullrich Kauczor; Lars Grenacher; Miriam Klauss
Journal:  Br J Radiol       Date:  2016-03-09       Impact factor: 3.039

9.  Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis.

Authors:  Edward S Huang; G Scott Gazelle; Chin Hur
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

10.  Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Mathieu Daudé; Fabrice Muscari; Camille Buscail; Nicolas Carrère; Philippe Otal; Janick Selves; Louis Buscail; Barbara Bournet
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.